ImpediMed (ASX:IPD) said that the increase in its US sales in the fiscal fourth quarter qualified it for an additional tranche 2 funding of $5 million under a capital growth facility with SWK Funding, according to a Wednesday Australian bourse filing.
US sales for the June quarter came in at 44 units, rising 100% from the previous quarter and 91% from the year-ago quarter. The total contract value for the fiscal fourth quarter came in at AU$6.3 million, jumping 29% from the prior quarter.
The firm executed an agreement for a five-year $15 million growth capital debt facility with SWK Funding in February. Funds under the facility will be used to support growth and commercialization activities.
Its shares jumped 13% on market close.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.